SCHEMBL1008405

SCHEMBL1008405

O=C(c1ccccc1O)N1CCCC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.65
POLB P06746 2/20 0.65
GAA P10253 2/20 0.65
KDM4E B2RXH2 1/20 0.65
HPGD P15428 4/20 0.61
ALDH1A1 P00352 2/20 0.61
HSD17B10 Q99714 2/20 0.61
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
ALOX15 P16050 1/20 0.61
TSHR P16473 1/20 0.61
RECQL P46063 1/20 0.61
HTT P42858 3/20 0.58
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
TP53BP1 Q12888 1/20 0.54
L3MBTL3 Q96JM7 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
MGLL Q99685 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30203951 1.00 MAPT (0.65) MAPTPOLBGAAKDM4EHPGD
SCHEMBL4057568 0.98 MAPT (0.68) MAPTPOLBGAAKDM4EHPGD
SCHEMBL2302971 0.98 MAPT (0.68) MAPTPOLBGAAKDM4EHPGD
SCHEMBL29940966 0.96 HTT (0.62) MAPTPOLBGAAKDM4EHPGD
SCHEMBL14511319 0.96 HTT (0.62) MAPTPOLBGAAKDM4EHPGD
SCHEMBL11718417 0.92 MEN1 (0.61) MAPTPOLBGAAKDM4EHPGD
SCHEMBL31347868 0.92 MEN1 (0.61) MAPTPOLBGAAKDM4EHPGD
SCHEMBL10720608 0.87 TSHR (0.69) MAPTPOLBGAAKDM4EHPGD
SCHEMBL667784 0.83 MGLL (0.50) MAPTPOLBGAAKDM4EHPGD
SCHEMBL9725169 0.83 MAPT (0.69) MAPTPOLBGAAKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11066407-B2 Preparation of certain substituted 1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereof INTRA-CELLULAR THERAPIES, INC. (US) 2021-07-20 US claimed
US-20200115380-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA-CELLULAR THERAPIES, INC. (US) 2020-04-16 US claimed
US-10597395-B2 Preparation of certain substituted 1-(4-fluorophenyl)-4-(2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-YL)butan-1-ones and pharmaceutically acceptable salts thereof INTRA-CELLULAR THERAPIES, INC. (US) 2020-03-24 US claimed
US-20190218219-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA-CELLULAR THERAPIES, INC. (US) 2019-07-18 US claimed
US-20260098040-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA CELLULAR THERAPIES INC (US) 2026-04-09 US disclosed
EP-3609891-B1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA CELLULAR THERAPIES INC (US) 2026-02-11 EP disclosed
US-12442027-B2 Method of reducing aromatic nitro compounds AMGEN INC. (US) 2025-10-14 US disclosed
EP-3898581-B1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA CELLULAR THERAPIES INC (US) 2025-08-27 EP disclosed
US-12358916-B2 Substituted heterocycle fused gamma-carbolines synthesis INTRA-CELLULAR THERAPIES, INC. (US) 2025-07-15 US disclosed
US-12297200-B2 Substituted heterocycle fused gamma-carbolines synthesis INTRA-CELLULAR THERAPIES, INC. (US) 2025-05-13 US disclosed
US-20250101022-A1 PROCESS FOR PREPARING INTERMEDIATES FOR 1-(4-FLUOROPHENYL)-4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3’,4’:4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)BUTAN-1-ONE INTRA-CELLULAR THERAPIES, INC. (US) 2025-03-27 US disclosed
US-12162816-B2 Method of reducing aromatic nitro compounds JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2024-12-10 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2008129288-A2 DISULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-10-30 WO disclosed
WO-2008112280-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA-CELLULAR THERAPIES, INC. (US) 2008-09-18 WO disclosed
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative MSD K.K. (JP) 2008-03-20 US disclosed
EP-1702919-A1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-09-20 EP disclosed
US-4962104-A FUNGICIDES BAYER AKTIENGESELLSCHAFT (DE) 1990-10-09 US disclosed
EP-0374559-A2 Substituted-2-phenyl-2,2-difluoroethyl thiocarbonates, process for their preparation and their use as herbicides BAYER AG (DE) 1990-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218219-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS CYCS, HCCS, IDH3B MAPT 4046/4885POLB 552/4885GAA 2263/4885
US-12358916-B2 Substituted heterocycle fused gamma-carbolines synthesis HCCS, CYCS, CBR3 MAPT 4107/4885POLB 791/4885GAA 2047/4885
US-12442027-B2 Method of reducing aromatic nitro compounds NNMT, CBR3, DHFR MAPT 3186/4885POLB 576/4885GAA 977/4885
US-20250101022-A1 PROCESS FOR PREPARING INTERMEDIATES FOR 1-(4-FLUOROPHENYL)-4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3’,4’:4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)BUTAN-1-ONE CYP1B1, CYP4B1, CBR1 MAPT 4017/4885POLB 609/4885GAA 3064/4885
US-12162816-B2 Method of reducing aromatic nitro compounds TYR, COMT, TH MAPT 2470/4885POLB 1098/4885GAA 981/4885
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 MAPT 4151/4885POLB 1255/4885GAA 84/4885
US-10597395-B2 Preparation of certain substituted 1-(4-fluorophenyl)-4-(2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-YL)butan-1-ones and pharmaceutically acceptable salts thereof CYP3A7, CYP4B1, CYP1B1 MAPT 3657/4885POLB 1701/4885GAA 1246/4885
US-20260098040-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS KCNH2, KCNH3, KCNH1 MAPT 4875/4885POLB 271/4885GAA 2708/4885
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK MAPT 3782/4885POLB 2078/4885GAA 83/4885
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative GCK, GCKR, HK1 MAPT 3676/4885POLB 3730/4885GAA 86/4885
US-11066407-B2 Preparation of certain substituted 1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereof CYP2F1, CYP3A4, CYP4F2 MAPT 3799/4885POLB 1801/4885GAA 1854/4885
US-12297200-B2 Substituted heterocycle fused gamma-carbolines synthesis HCCS, CYCS, CBR3 MAPT 4107/4885POLB 791/4885GAA 2047/4885
US-20200115380-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS HCCS, CYCS, CBR3 MAPT 4094/4885POLB 715/4885GAA 2311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.